Securities code: Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) securities abbreviation: Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) Announcement No.: 2022014 Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399)
Announcement on applying for credit line and providing guarantee from banks in 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Application for credit and guarantee from banks in 2022
In order to meet the operation and business development needs of the company and its subsidiaries / sub subsidiaries, the company and its wholly-owned subsidiaries hepalinkusa Inc. (hereinafter referred to as "the United States Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) hong Kong) Co., Ltd. (hereinafter referred to as" Hong Kong Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) hong Kong "), its wholly-owned subsidiaries Shenzhen Tiandao Pharmaceutical Co., Ltd. (hereinafter referred to as" Tiandao pharmaceutical "), Tiandao Pharmaceutical (Hong Kong) Co., Ltd. (hereinafter referred to as" Tiandao Hong Kong ") SPL acquisition Corp. (hereinafter referred to as "SPL") plans to apply for comprehensive credit lines (including renewal of due credit lines) from banks in 2022. In addition, the company and its subsidiaries / grandchildren intend to provide guarantee to the bank for the above-mentioned credit line.
(I) proposed credit extension
By the end of 2021, the company and its subsidiaries / grandchildren had obtained bank credit totaling about 103956055 million yuan, and the actual use limit was about 4018578 million yuan. The proposed credit line (equivalent to RMB) of the company and its subsidiaries / grandchildren in 2022 is expected to be as follows:
Application unit credit amount (10000 yuan) purpose credit conditions shareholding ratio
Medium and long term fixed asset loans, medium and long term companies and subsidiaries dopu
Current capital loan, short-term current loan and partial asset mortgage/
Company capital loan, trade financing line, pledge, dopoule, Tianyi
920000 financing guarantee, procurement of raw materials-
Daily operation turnover, replacement of other banks and provision of joint and several liabilities by loanword medicine
Payment, export documentary bill and other guarantees
Medium and long term fixed asset loans
Current fund loan and short-term current
Hong Kong Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) capital loan, trade financing line, 30000 financing guarantee provided by the company to its wholly-owned subsidiary with joint and several liability, procurement of raw materials
Guarantee
Daily operation turnover and replacement of loans from other banks
Payment, export documentary bill, etc
Medium and long term fixed asset loans, medium and long term
Current fund loan and short-term current
Tiandao Hong Kong capital loan, trade financing line, 20000 financing guarantee provided by the company to the wholly-owned subsidiary of joint and several liability, procurement of raw materials
Guarantee the daily operation turnover of the wholly-owned subsidiary and replace the loans of other banks
Payment, export documentary bill, etc
Medium and long term fixed asset loans
Current fund loan and short-term current
Us Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) 20000 capital loan, trade financing line, financing guarantee of joint and several liability wholly-owned subsidiary provided by the company, procurement of raw materials and guarantee
Daily operation turnover and replacement of loans from other banks
Payment, export documentary bill, etc
Medium and long term fixed asset loans
Current fund loan and short-term current
SPL 70000 capital loan, trade financing line, SPL self owned assets mortgage, wholly-owned subsidiary financing guarantee, purchase of raw materials
Daily operation turnover and replacement of loans from other banks
Payment, export documentary bill, etc
Medium and long term fixed asset loans
Short term Liquidity
Tiandao pharmaceutical 400000 capital loan, trade financing line, financing guarantee of wholly-owned subsidiaries, procurement of raw materials and joint and several liability guarantee provided by the company and dopoule
Daily operation turnover and replacement of loans from other banks
Payment, export documentary bill, etc
Total 1460000 ---
(II) proposed guarantee
The amount of guarantee to be provided by the company to its subsidiaries / grandchildren in 2022 is estimated as follows:
Whether the proportion of the guarantor holding the guaranteed party's proposed guarantee amount up to 2022 is the proportion of the guarantor's guaranteed party's shares, the asset guarantee balance in the recent period (10000 guarantee amount, the latest related liability ratio of the municipal company, yuan) and the proportion of net assets in the recent period (10000 yuan)
Company, multi
Pule, Tian Hong Kong Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) 100% 143.32% - Beijing Ultrapower Software Co.Ltd(300002) .63% no way medicine
Tiandao Hong Kong 100% 83.13% - 200001.75% no
Company USA Shenzhen Hepalink Pharmaceutical Group Co.Ltd(002399) 100% 141.30% - 200001.75% no
Company, duotiandao pharmaceutical 100% 157.73% 1108835440 China Tianying Inc(000035) .05% noprole
Total 1108835447000041.19%
The board of directors of the company requests the general meeting of shareholders to authorize the chairman of the company to handle the relevant procedures of bank credit business and guarantee within the above limit, including but not limited to specific negotiation with the bank, signing relevant agreements and applying for loans; At the same time, the general meeting of shareholders is requested to authorize the chairman of the company to adjust the guarantee amount to be provided within the scope of the above subsidiaries / grandchildren according to the actual needs in the business process. Finally, the total guarantee amount of the company (including subsidiaries / grandchildren) in 2022 will not exceed the guarantee amount granted this time, and the validity period is from the date of deliberation and approval of the 2021 annual general meeting of shareholders to the date of holding the next annual general meeting of shareholders.
The above matters have been deliberated and approved at the 17th meeting of the 5th board of directors of the company, and need to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation and approval by special resolution.
1. Company name: Shenzhen Tiandao Pharmaceutical Co., Ltd
Unified social credit Code: 91440 Ginlong Technologies Co.Ltd(300763) 486555h
Date of establishment: June 29, 2004
Registered address: No. 1, Rongtian south, Kengzi street, Pingshan New District, Shenzhen
Legal representative: Li Li
Registered capital: 768 million yuan
Main business: R & D, production and sales of enoxaparin sodium API and enoxaparin sodium preparation
Relationship with listed companies: wholly owned subsidiaries
Whether it is a dishonest executee: no
Major pending litigation, arbitration and other disputes: None
Main financial data of the last year:
Unit: Yuan
Project December 31, 2021
Total assets 455595511821
Total liabilities 288839109746
Net assets 166756402075
Asset liability ratio 157.73%
Current assets 415285768262
Current liabilities 288528220121
Project 2021
Operating income 291962900753
Total profit 9942229679
Net profit 9902458728
2. Company name: Hepalink USA Inc
Date of establishment: October 25, 2013
Total investment: USD 18790100
Address: Corporation Trust Center, 1209 orange street, Wilmington, New Castle County, Delaware 19801
Main business: import and export trade
Relationship with listed companies: wholly owned subsidiaries
Whether it is a dishonest executee: no
Major pending litigation, arbitration and other disputes: None
Main financial data of the last year:
Unit: Yuan
Project December 31, 2021
Total assets 560198097360
Total liabilities 396447453465
Net assets 163750643895
Asset liability ratio 141.30%
